Evaluating whether Nyxoah (NASDAQ / Euronext: NYXH) represents a sound equity investment requires balancing its promising medical device pipeline against the financial realities typical of clinical-stage healthcare firms. The company develops innovative neurostimulation technologies for treating obstructive sleep apnea, but like many pre-profit medical device developers, it incurs ongoing operational losses and capital burn, leading analysts to classify it as a high-risk, high-reward growth asset.